Why are hormone levels so erratic during perimenopause?

During perimenopause, the body is trying to ovulate with a limited number of eggs. The brain's signals (FSH) to the ovaries cause an inconsistent response, leading to wild fluctuations in estrogen, sometimes very high and sometimes very low, causing diverse symptoms.

What are the long-term health risks of not taking hormone therapy after menopause?

Not taking hormone therapy in post-menopause significantly increases risks of recurrent urinary tract infections, pelvic pain, osteoporosis, dementia, Alzheimer's, heart disease, and colon cancer. It also worsens mental health.

How did the Women's Health Initiative (WHI) misinterpret its data on HRT?

The WHI study found a 24% relative risk increase in breast cancer incidence for women on synthetic progesterone and estrogen, but the absolute risk was a mere 0.1%. Positive findings like decreased colon cancer, fractures, diabetes, and overall mortality were downplayed or not reported in the initial press conference, leading to widespread fear and a decline in HRT use.

Why is there a 'brain drain' in menopause education among doctors?

Less than 6% of internal medicine, OB/GYN, or family practice doctors receive even an hour of menopause education in their training. This lack of knowledge, coupled with past misinformation and the industry's shift away from women's health, has created a generation of doctors unable or unwilling to prescribe HRT.

What is the role of testosterone in women's health, and when does it decline?

Testosterone is crucial for women's sexual health, libido, and even urinary tract function, with women having significantly more testosterone than estradiol. Its levels begin to decline in a woman's 30s, independent of menopause, contributing to low libido, UTIs, and pelvic pain.

What are common side effects of testosterone therapy in women, and how are they managed?

The most common side effect of appropriate-dose topical testosterone in women is acne. Increased hair growth may also occur. These are typically manageable by adjusting the dose, and the most dramatic side effects like voice deepening or clitoromegaly are rare with low-dose topical application.

Why is there no FDA-approved testosterone product for women in the US?

Despite a billion-dollar, five-year study showing a female testosterone formulation to be safe and effective, the FDA required five more years of data and another billion-dollar study, citing women's breast tissue. This 'goalpost move' caused companies to abandon development, leaving no FDA-approved option for women in the US (though Australia has one).

What are the diverse systemic symptoms of menopause beyond hot flashes?

Menopause is a whole-body experience due to hormone receptors throughout the body. Symptoms include hot flashes (which can indicate cardiovascular risk), night sweats, joint pain, frozen shoulder, plantar fasciitis, sleep issues, mood changes, bleeding irregularities, low libido, orgasm and arousal problems, pain with sex, brain fog, and depression.

What is Genitourinary Syndrome of Menopause (GSM), and why are vaginal hormones crucial?

GSM is the modern term for vulvovaginal atrophy, encompassing urinary frequency, urgency, dryness, leakage, and recurrent UTIs caused by declining hormones. Low-dose vaginal estrogen or DHEA can reduce UTI risk by over 50%, increase lubrication and arousal, and are safe even for elderly women and those with a history of breast cancer.

Is it too late to start hormone therapy if a woman is several years post-menopause?

No, it is generally not too late. The 'timing hypothesis' suggesting a strict window for HRT initiation, based on older data and synthetic hormones, is under question. Individual benefits for bone health, sexual health, and mental well-being should be considered through shared decision-making.

Should women stop hormone therapy after 10 years?

There is no data to suggest routinely stopping HRT after a certain duration like 10 years. In fact, stopping hormone therapy can reverse bone density gains and potentially disrupt cardiovascular health. Unless there's an active hormone-sensitive cancer, continuing therapy is generally recommended.

How should HRT be approached for women with a history or risk of breast cancer?

For women with a family history or DCIS (non-cancerous increase in risk), HRT can often be considered, as the risks of not taking hormones (e.g., bone loss, cardiovascular disease) are significant. For active or treated breast cancer, there's emerging discussion about using HRT, especially considering that 'estrogen fuels cancer' is often an oversimplified fear-based message.

What are red flags for exploitative hormone therapy practices?

Be suspicious if a doctor only offers one type of hormone therapy, charges thousands for expensive products (especially pellets) with a requirement to 'insert into your butt' multiple times a year, sells their own compounded products as 'safer' or 'more effective' without evidence, or requires costly, esoteric saliva-based lab testing. These are often signs of practices that exploit patients.

Key Moments

348 ‒ Women’s sexual health, menopause, and hormone replacement therapy (HRT)

Peter Attia MD

Science & Technology4 min read145 min video

May 12, 2025|303,959 views|8,327|1,101

Peter Attia MD Dr. Peter Attia Early Medical The Drive Podcast The Drive Longevity Zone 2

Save to Pod

Key Moments

TL;DR

Women's sexual health, menopause, and HRT are neglected, with outdated fears and lack of doctor education harming health outcomes.

Key Insights

The medical field has significantly neglected women's sexual health and menopause, leading to a lack of education and effective treatment.

Misinterpretation of the Women's Health Initiative (WHI) study created widespread fear and has prevented many women from accessing beneficial hormone replacement therapy (HRT).

Testosterone plays a crucial role in women's health, impacting libido, energy, and potentially mood, yet it is often overlooked.

Vaginal estrogen and DHEA are safe and effective for treating genitourinary symptoms of menopause, reducing UTI risk, and improving quality of life, with significant economic benefits.

The lack of standardized education on menopause and HRT for healthcare providers is a major barrier to proper patient care, creating a 'lost generation' of doctors.

Fear and outdated information often lead to suboptimal or even harmful 'fringe' practices in hormone therapy, underscoring the need for evidence-based, accessible care.

THE NEGLECT OF WOMEN'S SEXUAL HEALTH AND MENOPAUSE

The conversation highlights a significant gap in medical education and practice regarding women's sexual health and menopause. Dr. Rachel Rubin, a urologist specializing in sexual health, emphasizes that this area is severely underrepresented, leading to a lack of information and effective treatment options for women. This neglect results in a population suffering from preventable issues, while the medical community lacks the knowledge to adequately address them. Rubin points out that societal and medical biases have created a situation where men's sexual health is far better understood and treated.

THE MISINTERPRETATION OF THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY

A major focus is the profound negative impact of the misinterpretation of the WHI study results. The study, intended to provide critical data on hormone therapy (HT), was sensationalized and led to widespread fear, causing a drastic decline in HRT prescriptions. The speaker argues that the data was drastically misinterpreted, leading an entire generation of doctors to fear prescribing hormones. This has resulted in significant harm to women's health, as the benefits of HRT, such as reduced risk of fractures, diabetes, and certain cancers, were overlooked due to this fear-based approach.

HORMONAL CHANGES DURING PERIMENOPAUSE AND MENOPAUSE

The discussion explains the complex hormonal shifts women experience. Perimenopause is characterized by erratic fluctuations in estrogen, progesterone, and testosterone, likened to an unstable gas tank that overfills and then empties unpredictably. Menopause, in contrast, represents an 'empty gas tank' with a significant loss of these hormones. This transition is contrasted with men's more gradual hormonal decline. The physiological process of the menstrual cycle, driven by hormones like FSH and LH, is detailed, illustrating how these fluctuations lead to the symptoms experienced during perimenopause and menopause.

THE CRITICAL ROLE OF TESTOSTERONE IN WOMEN'S HEALTH

Testosterone, often overlooked in women's health, is highlighted as a critical hormone essential for libido, energy, and overall well-being. Contrary to the misconception that women primarily need estrogen, they possess significant amounts of testosterone, which also declines with age. The conversation stresses that this decline can lead to issues beyond low libido, affecting the urinary tract, mood, and cognitive function. The lack of FDA-approved testosterone formulations for women and the general lack of education on its use contribute to its underutilization, despite global consensus on its benefits for low libido.

SYSTEMIC AND LOCALIZED HORMONE THERAPY OPTIONS

Various methods for administering hormone therapy are explored, including patches, gels, oral medications, and vaginal rings for systemic effects, and localized treatments like vaginal estrogen and DHEA. The importance of personalized treatment is emphasized, as different individuals respond differently to various formulations and doses. The discussion differentiates systemic therapy for whole-body benefits from local vaginal treatments, which are primarily for genitourinary symptoms and are considered extremely safe for nearly all women, regardless of medical history, offering significant improvements in quality of life and infection prevention.

ADDRESSING GENITOURINARY SYMPTOMS AND PREVALENCE OF UTIS

The genitourinary syndrome of menopause (GSM), including urinary frequency, urgency, incontinence, and recurrent urinary tract infections (UTIs), is presented as a major health issue, particularly for older women. Vaginal estrogen and DHEA are identified as highly effective treatments, significantly reducing UTI risk (by over 50%) and improving urinary and sexual health. The immense economic burden of UTIs on healthcare systems, including hospitalizations and ICU stays for sepsis, is highlighted, with estimates suggesting billions in savings for Medicare if vaginal estrogen were widely used. This underscores a critical public health problem rooted in a lack of awareness and appropriate treatment.

THE CHALLENGES AND FUTURE OF MENOPAUSE CARE

The conversation identifies a 'humility problem' and resistance to change within the medical community as major obstacles. There's a critical shortage of healthcare providers trained in menopause management, leading to a 'brain drain' and a 'lost generation' of practitioners. The discussion also warns against exploitative 'fringe' practices, such as pellet clinics and compounding pharmacies, that may lack scientific rigor or overcharge patients. The need for evidence-based education, self-advocacy by patients, and a broader understanding of menopause as a whole-body issue, not just hot flashes, is crucial for improving women's long-term health and quality of life.

Mentioned in This Episode

●Products

●Companies

●Organizations

●Books

●Studies Cited

●Concepts

●People Referenced

Common Questions

The 'gas tank' analogy describes menopause as a sudden and complete emptying of a woman's hormone tank, in contrast to men's gradual decline. Perimenopause, the transition phase, is characterized by erratic fluctuations, where the tank can be overflowing or rapidly emptying.

Topics

Hormone Replacement Therapy (HRT)Urology WHI Study Genitourinary Syndrome Of Menopause (GSM)Urinary Tract Infections (UTI)Shared Decision-Making FDA Regulation Compounded Hormones

Mentioned in this video

bookThe Menopause Manifesto

Another great book on menopause, providing educational resources for women.

companyGoodRx

A platform mentioned alongside Mark Cuban's efforts to make medications like vaginal estrogen more affordable.

personHeather Hirsch

Author of 'Pick Your Menopause Type', a recommended book on menopause.

conceptGABA receptor

Receptors in the brain that may explain varying degrees of sensitivity to progesterone and its metabolites, influencing mood and sleep.

personMatt Lauer

Mentioned in the context of the WHI press conference, implying the sensational media coverage of the study's initial findings.

organizationInternational Society for the Study of Women's Sexual Health (ISSWSH)

A fabulous organization that provides guidelines and resources for women's sexual health, including appropriate dosing for testosterone therapy in females.

personTamsin Fidoletti

A reporter who wrote a book about menopause, recommended as a resource.

productNatesto

A nasal gel formulation of testosterone, FDA-approved for men, but not commonly used by the speaker due to messiness and alcohol content.

studyTraverse study

A study that led to the removal of cardiovascular disease risk labeling for testosterone therapy in men, despite some criticism of its design.

personMaria Shriver

Supported Lis Mosconi's research on estrogen receptors in the brain with significant funding.

bookPick Your Menopause Type

A book by Heather Hirsch, offering different approaches to menopause, recommended for self-education.

conceptDunning-Kruger curve

A cognitive bias where people with low ability at a task overestimate their own ability; used as an analogy for social media 'experts' in hormone therapy.

productIntrarosa

An FDA-approved vaginal DHEA product that helps the vulvar vestibule tissue with both estrogen and androgen receptors.

bookEstrogen Matters

A book by oncologist Avrum Bluming, questioning research on HRT and breast cancer, recommended for those doing their own research.